What does adagrasib do?

Adagrasib (Adagrasib) is an inhibitor of the RAS GTPase family. Adagrasiib is specifically indicated: as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, as determined by a U.S. FDA-approved test, who have received at least one prior systemic therapy; and in combination with cetuximab, for the treatment of locally advanced or metastatic CRC with a KRAS G12C mutation, as determined by an FDA-approved test. of adult patients who had previously received chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan.

These indications are approved on an accelerated basis based on objective response rate (ORR) and duration of response (DOR). Continued approval for these indications may be dependent on verification and description of clinical benefit in confirmatory trials.

Adagrasib is an irreversible inhibitor of KRAS G12C that covalently binds to the mutated cysteine in KRAS G12C and locks the mutated KRAS protein in an inactive state, preventing downstream signaling without affecting wild-type KRAS protein. Adagrasib inhibits tumor cell growth and viability in cells harboring the KRAS G12C mutation and causes tumor regression in a KRAS G12C mutant tumor xenograft model with minimal off-target activity.

In general, adagrasib, as a new treatment for non-small cell lung cancer and colorectal cancer, provides new hope for patients with KRAS G12C mutations. However, the above information is for reference only, and patients must strictly follow the doctor's instructions during use to ensure the best treatment effect and minimize the occurrence of adverse reactions.